We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
RavenQuest BioMed Inc | CSE:RQB | CSE | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.005 | 0.005 | 0.20 | 0 | 00:00:00 |
“As RavenQuest evolves toward profitability, the composition of our board has taken shape to reflect our plans for 2020 and beyond," said George Robinson, RavenQuest CEO. "To fully realize our potential moving forward, I’m confident recent changes at the board level will provide impactful leadership and perspective as we transition from a start-up into an operating company.” Robinson continued.
Cassidy McCord
Ms. McCord has a medicinal cannabis background, focusing on company reorganization and patient processing. She has also held the position of director for a publicly traded cannabis company and also holds a business administration diploma from Vancouver Island University
For more information, access RavenQuest’s investor presentation, fact sheet and videos here.
Follow RavenQuest:TwitterInstagramFacebookLinkedIn
About RavenQuest BioMed Inc.
RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company also focuses on partnerships with Indigenous communities.
On Behalf of the Board of Directors ofRAVENQUEST BIOMED INC.
“George Robinson”Chief Executive Officer
For further information, please contact: Mathieu McDonald, Corporate Communications1-877-282-1586
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
1 Year RavenQuest BioMed Chart |
1 Month RavenQuest BioMed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions